archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Full Year results Announcements 2012/13
    June 2013 up US 192 million or 19 on a reported basis when compared to the prior comparable period PCP The result included an unfavourable foreign exchange impact of US 18 million On a constant currency 1 basis net profit after tax grew 21 slightly ahead of guidance Earnings per share grew 24 benefiting from current and past capital management initiatives Download this release CSL Full Year results announcement for

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931748396/prdetail.htm (2014-01-05)
    Open archived version from archive


  • CSL announces Changes to the Board
    that Mr Ian Renard AM has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company s Annual General Meeting on 16 October 2013 Ms McDonald is currently a Partner of Ashurst She has a strong background in corporate and commercial law including mergers and acquisitions corporate governance continuous disclosure related party transactions buybacks and capital raisings Ms McDonald is currently Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia having previously been a Deputy Chair and was also a member of the Australian Takeovers Panel from 2001 to 2010 In addition to her legal qualifications Marie has completed a Bachelor of Science Hons degree CSL s Chairman Professor John Shine AO said I am delighted that we have been able to appoint a lawyer with Marie s experience and qualification I am certain that she will make a significant contribution to the Company Mr Renard has been a Director of the Company since August 1998 He has been a Member of CSL s Audit and Risk Management Committee since 1998 and has been Chairman of that Committee since October 2008 During this time he has been a strong supporter of the Company s international expansion plans which have helped transform CSL into the global speciality biopharmaceutical company that it is today Prior to becoming a Director of CSL in his capacity at that time as a Partner of Arthur Robinson Hedderwicks Mr Renard was appointed to advise the Board of CSL in the privatisation of CSL and successful listing of CSL on the Australian Securities Exchange in May 1994 Professor John Shine said Ian has been a very valuable contributor to the Board over an extended period especially in his capacity as a member of

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931748562/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Notice of Investor/Analyst Briefing - Result FY2013
    Result FY2013 Melbourne Australia 08 08 2013 CSL Limited ASX CSL CSL Limited s 2013 full year results will be announced on Wednesday 14 August 2013 A briefing for investors and analysts will be held at 11am Australian Eastern Standard Time on Wednesday 14 August 2013 This briefing will be webcast live at www csl com au in the Investors section and will also be archived on the site later

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931709204/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL progresses new bleeding disorder therapies
    fusion clotting factors and has shown the technology is able to extend the effect of the treatment We are very encouraged by the results of our clinical studies which aim to develop longer acting and more effective products for people with haemophilia said Dr Russell Basser CSL Senior Vice President Global Clinical Research and Development The investigation of novel ways to extend the life of recombinant clotting factors in patients may result in a significant reduction in the number of weekly infusions for people with haemophilia The study results were presented at the International Society of Thrombosis and Haemostasis congress in Amsterdam this week These promising data provides CSL the evidence needed to advance the studies to completion Further clinical studies are being planned for other recombinant clotting factors in development and are expected to be the first therapies produced in CSL Behring s new Biotechnology Facility in Broadmeadows Melbourne This world class facility is the largest of its kind in Australia and was constructed to support the late stage development of novel recombinant therapies in our R D pipeline said General Manager of CSL Behring Australia Dr Simon Green The recently completed facility is currently producing test batches of recombinant proteins and is on track to start manufacture of clinical trial material early next year Download this release CSL progresses new bleeding disorder therapies 0 20Mb Media contact Sharon McHale Senior Director Public Affairs CSL Limited Mobile 614 0997 8314 Email sharon mchale csl com au About the studies For more information about the studies presented at the International Society of Thrombosis and Haemostasis congress visit 1 Phase I Results From Study of Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin rVIIa FP in Healthy Volunteers 2 Results from Study of Recombinant Single Chain Factor VIII rVIII SingleChain

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931560067/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Terms of Departure of Managing Director and CEO
    has previously announced that Dr Brian McNamee will be succeeded by Mr Paul Perreault as Managing Director and Chief Executive Officer of CSL from 1 July 2013 Dr McNamee s leadership drive and strategic vision over his 23 years as Managing Director and Chief Executive Officer were instrumental in building the Company into the exceptional global biopharmaceutical enterprise it is today During this time the Company has delivered exceptional growth in shareholder value On behalf of the Board and all employees of CSL I would like to thank Dr McNamee and to wish him every success in the future said CSL s Chairman Professor John Shine AO Dr McNamee has worked collaboratively with the Board and his successor Mr Perreault over an extended period to ensure a smooth transition in the best interests of the Company This includes Dr McNamee s agreement to remain available to the Company during the period 1 July to 15 October 2013 The details of Dr McNamee s benefits in connection with the cessation of his employment with the Company are set out in the Attachment While most aspects of Dr McNamee s benefits have already been approved by the Board the Board intends to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931529049/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited - Changes to Segment Reporting
    News by Date Contact CSL Home Newsroom CSL Limited Changes to Segment Reporting CSL Limited Changes to Segment Reporting Melbourne Australia 19 06 2013 In February 2013 the Company announced the completion of the reorganisation of its Australian Operations which took effect from 1 January 2013 and advised that financial reporting reflecting this new organisational structure would be shown in the segment reporting commencing with the FY2013 results These will be announced on 14 August 2013 To assist investors during the transition to the new segment reporting structure the Company is today lodging with the Australian Securities Exchange the revised segment disclosures for the financial year ended 30 June 2012 and the half year ended 31 December 2012 The attached segment disclosures are unaudited but have been subject to Agreed Upon Procedures carried out by Ernst Young We expect these to form the prior comparable period disclosures in Note 2 of the CSL Group Financial Statements for the full year ended 30 June 2013 to be audited by Ernst Young and the half year ended 31 December 2013 to be reviewed by Ernst Young A description of the changes to the segment structure is included in the attached notes Download

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931478572/prdetail.htm (2014-01-05)
    Open archived version from archive

  • bioCSL Goes Back into Influenza Vaccine Production for Australia
    end of May and will be prioritised for age appropriate at risk groups under the National Immunisation Program bioCSL General Manager Dr John Anderson said the demand for influenza vaccine had increased significantly in the first two weeks of April in both the public and private markets All our customers are reporting a much earlier and much higher uptake of influenza vaccine this year compared to the last few years bioCSL is the only manufacturer of influenza vaccine in the Southern Hemisphere and is a major supplier of seasonal and pandemic influenza vaccines to the Australian market The company also supplies influenza vaccine to overseas markets including the US UK and New Zealand Dr Anderson said that bioCSL was in the midst of producing a new formulation of influenza vaccine for the forthcoming Northern Hemisphere season when it made the decision to go back into production for Australia Restarting production of Southern Hemisphere influenza vaccine is a significant undertaking but as Australia s only on shore manufacturer we are committed to responding to local needs Should the extraordinarily high demand for influenza vaccine persist we are very pleased to be able to support the Government in ensuring additional doses are

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931255978/prdetail.htm (2014-01-05)
    Open archived version from archive

  • bioCSL Awarded Major Vaccine Distribution Contracts
    Awarded Major Vaccine Distribution Contracts Melbourne Australia 29 04 2013 bioCSL has been selected by New South Wales Health NSW Health and the Western Australian Department of Health WA DoH to provide storage and distribution services for government funded vaccine programs The contracts awarded after separate tender processes have a combined value of 6 8 million Under a three year agreement with WA DoH bioCSL s contract logistics business will manage the storage and distribution of over one million vaccines per year distributing to 528 metropolitan and 297 regional immunisation service providers bioCSL s appointment of a two year contract with NSW Health includes approximately 50 000 deliveries of vaccines each year to over 5 000 private and public immunisation service providers These vaccines encompass those covered under the National Immunisation Program NIP and additional vaccines for outbreaks and public health response measures Operating since 1992 bioCSL has national warehouses and offices spanning five states and provides third party logistics services to both government and commercial enterprises bioCSL s Vice President of Operations Stephen Marlow says the Company is committed to providing logistics services for this important component of health service delivery bioCSL is pleased to be able to support

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1255931252667/prdetail.htm (2014-01-05)
    Open archived version from archive